Vorinostat interferes with Wnt and NF-κB pathways in the M-07e cell line

Leukemia

Volumn 23, Issue 10, 2009, Pages 1935-1938

  Galimberti, S ^a   Canestraro, M ^a   Maffei, R ^b   Marasca, R ^b   Guerrini, F ^a   Piaggi, S ^a   Ciabatti, E ^a   Petrini, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR7; DEATH RECEPTOR 3; FAS ANTIGEN; GAMMA INTERFERON RECEPTOR 1; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 6; LIPOCORTIN 5; PROTEIN CARD10; PROTEIN CARD8; PROTEIN CARD9; PROTEIN KREMEN2; PROTEIN UBE2G1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; VORINOSTAT; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN M 07E; CELL SURVIVAL; CYTOTOXICITY; DNA REPAIR; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG SCREENING; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STAINING; UBIQUITINATION; UPREGULATION;

EID: 70350103088     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.119     Document Type: Article

References (8)

1. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3 beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
2. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
3. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281: 5612-5622.
4. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
5. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M et al. Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2008; 140: 394-401.
6. Galimberti S, Canestraro M, Khan R, Buda G, Orciuolo E, Guerrini F et al. Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. Leukemia 2008; 22: 628-631.
7. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L et al. PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 2008; 32 103-112.
8. Blumenthal A, Ehlers S, Lauber J, Buer J, Lange C, Goldmann T et al The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006; 108: 965-973.